EGFR Inhibitor Response Markers
EGFR inhibitor sensitivity: EGFR mutation
Schilder, R.J., Sill, M.W., Chen, X., Darcy, K.M., Decesare, S.L., Lewandowski, G., Lee, R.B., Arciero, C.A., Wu, H., and Godwin, A.K. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11: 5539-5548.
Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Jr., Franklin, W.A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., et al. (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034-5042.
Brugger, W., Triller, N., Blasinska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G.M., Mazieres, J., Whittom, R., Ward, C., Mayne, K., et al. (2011). Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29: 4113-4120.
EGFR inhibitor sensitivity: EGFR copy number
Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L.L., Cavalli, F., and Mazzucchelli, L. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
Cappuzzo, F., Finocchiaro, G., Rossi, E., Janne, P.A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008). EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19: 717-723.
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
Dahabreh, I.J., Linardou, H., Kosmidis, P., Bafaloukos, D., and Murray, S. (2011). EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol. Ann Oncol. 22: 545-52.
Lee, Y., Shim, H.S., Park, M.S., Kim, J.H., Ha, S.J., Kim, S.H., and Cho, B.C. (2012). High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 18: 1760-1768.
EGFR inhibitor resistance: KRAS mutation
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.L., Peeters, M., Humblet, Y., et al. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
EGFR inhibitor resistance: BRAF mutation
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013). Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49.
EGFR inhibitor resistance: PIK3CA mutation
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.L., Peeters, M., Humblet, Y., et al. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
EGFR inhibitor resistance: PTEN loss
Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L.L., Cavalli, F., and Mazzucchelli, L. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.